Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.

N. Romeiro,G. Aguirre,Paola Hernández,Mercedes González,H. Cerecetto,I. Aldana,S. Pérez-Silanes,A. Monge,E. Barreiro,L. M. Lima

DOI: https://doi.org/10.1016/j.bmc.2008.11.065

IF: 3.461

2009-01-15

Bioorganic & Medicinal Chemistry

Abstract:

What problem does this paper attempt to address?

Plasma From Stored Packed Red Blood Cells And Mhc Class I Antibodies Causes Acute Lung Injury In A 2-Event In Vivo Rat Model

Marguerite R Kelher,Tomhiko Masuno,Ernest E Moore,Sagar Damle,Xianzhong Meng,Yong Song,Xiayuan Liang,Jerry Niedzinski,Steven S Geier,Samina Y Khan,Fabia Gamboni-Robertson,Christopher C Silliman

DOI: https://doi.org/10.1182/blood-2008-09-177857

IF: 20.3

2009-01-01

Blood

Abstract:Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion death. We hypothesize that TRALI requires 2 events: (1) the clinical condition of the patient and (2) the infusion of antibodies against MHC class I antigens or the plasma from stored blood. A2-event rat model was developed with saline (NS) or endotoxin (LPS) as the first event and the infusion of plasma from packed red blood cells (PRBCs) or antibodies (OX18 and OX27) against MHC class I antigens as the second event. ALI was determined by Evans blue dye leak from the plasma to the bronchoalveolar lavage fluid (BALF), protein and CINC-1 concentrations in the BALF, and the lung histology. NS-treated rats did not evidence ALI with any second events, and LPS did not cause ALI. LPS-treated animals demonstrated ALI in response to plasma from stored PRBCs, both prestorage leukoreduced and unmodified, and to OX18 and OX27, all in a concentration-dependent fashion. ALI was neutrophil (PMN) dependent, and OX18/OX27 localized to the PMN surface in vivo and primed the oxidase of rat PMNs. We conclude that TRALI is the result of 2 events with the second events consisting of the plasma from stored blood and antibodies that prime PMNs. (Blood. 2009; 113: 2079-2087)
A pulmonary endothelial amplification loop aggravates ex‐vivo transfusion‐related acute lung injury via increased toll‐like receptor 4 and intra‐cellular adhesion molecule‐1 expression

Sofia K. H. Morsing,Eveline Zeeuw van der Laan,Annemarieke D. Stalborch,Jaap D. Buul,Rick Kapur,Alexander P. Vlaar,Annemarieke D. van Stalborch,Jaap D. van Buul

DOI: https://doi.org/10.1111/trf.17076

2022-08-27

Transfusion

Abstract:Background Transfusion‐Related Acute Lung Injury (TRALI) is a life‐threatening complication of blood transfusions characterized by pulmonary endothelial cell damage and edema, with a high incidence in critically ill patients. The pathophysiology of TRALI is unresolved, but can generally be hypothesized to follow a 2‐hit model in which the first hit is elicited by the underlying clinical condition of the patient (e.g., inflammation, which can be reflected by LPS in experimental models), and the second hit is delivered by the blood transfusion product (e.g., HLA class I antibodies). Here, we report a synergistic role for LPS and HLA class I antibody binding to pulmonary endothelium resulting in enhanced inflammatory responses. Materials and Methods Pulmonary endothelial cells were treated with PBS or low‐dose LPS, exclusively or in combination with anti‐HLA class I. Endothelial surface expression of HLA class I, TLR4, and inflammatory marker ICAM‐1 were measured, and trans‐endothelial migration (TEM) of neutrophils was investigated. Results LPS treatment of pulmonary endothelium enhanced HLA class I antibody binding, and combined LPS and HLA class I antibody binding enhanced TLR4 (LPS receptor) and ICAM‐1 expression on the endothelial cell surface. Low‐dose LPS and HLA antibody together also increased neutrophil TEM under physiological flow by on average 5‐fold. Conclusion We conclude that LPS and anti‐HLA class I antibody have the ability to activate the pulmonary endothelium into a spiral of increasing inflammation, opening the opportunity to potentially block TLR4 to prevent or reduce the severity of TRALI in vivo.

hematology
Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies

Da-Wei Chen,Tian Kang,Xiu-Zhang Xu,Wen-Jie Xia,Xin Ye,Yong-Bin Wu,Yao-Ri Xu,Jing Liu,Hui Ren,Jing Deng,Yang-Kai Chen,Hao-Qiang Ding,Muhammad Aslam,Wioleta M. Zelek,B. Paul Morgan,Rick Kapur,Sentot Santoso,Yong-Shui Fu

DOI: https://doi.org/10.1172/jci.insight.165142

IF: 9.4958

2023-03-23

JCI Insight

Abstract:Anti-CD36 Abs have been suggested to induce transfusion-related acute lung injury (TRALI) upon blood transfusion, particularly in Asian populations. However, little is known about the pathological mechanism of anti-CD36 Ab–mediated TRALI, and potential therapies have not yet been identified. Here, we developed a murine model of anti-CD36 Ab–mediated TRALI to address these questions. Administration of mouse mAb against CD36 (mAb GZ1) or human anti-CD36 IgG, but not GZ1 F(ab′) 2 fragments, induced severe TRALI in Cd36 +/+ male mice. Predepletion of recipient monocytes or complement, but not neutrophils or platelets, prevented the development of murine TRALI. Moreover, plasma C5a levels after TRALI induction by anti-CD36 Abs increased more than 3-fold, implying a critical role of complement C5 activation in the mechanism of Fc-dependent anti-CD36–mediated TRALI. Administration of GZ1 F(ab′) 2 , antioxidant ( N -acetyl cysteine, NAC), or C5 blocker (mAb BB5.1) before TRALI induction completely protected mice from anti-CD36–mediated TRALI. Although no significant amelioration in TRALI was observed when mice were injected with GZ1 F(ab′) 2 after TRALI induction, significant improvement was achieved when mice were treated postinduction with NAC or anti-C5. Importantly, anti-C5 treatment completely rescued mice from TRALI, suggesting the potential role of existing anti-C5 drugs in the treatment of patients with TRALI caused by anti-CD36.

medicine, research & experimental
Sheet resistance measurement for process monitoring of 400 °C PureB deposition on Si

L. Qi,L. Nanver

DOI: https://doi.org/10.1109/ICMTS.2015.7106135

2015-03-23

Abstract:Sheet-resistance test-structures to determine conductance along the interface formed by 400°C pure boron (PureB) deposition on silicon are presented. The structures are straightforward to fabricate and measure for monitoring either directly after deposition or end-of-line. This provides valuable information on the perfection of the deposition and the series resistance of PureB (photo)diodes.
MEASUREMENT OF THE LONGITUDINAL POLARIZATION OF THE HERA ELECTRON BEAM USING CRYSTALS AND THE ZEUS LUMINOSITY MONITOR

K. Piotrzkowski

DOI: https://doi.org/10.1016/0168-583X(96)00314-X

1995-12-05

Abstract:
Transfusion-related acute lung injury following random donor platelet transfusion: a report of two cases

R K Ramanathan,D J Triulzi,T F Logan

DOI: https://doi.org/10.1046/j.1423-0410.1997.7310043.x

Abstract:Objectives: Transfusion-related acute lung injury (TRALI) following random donor platelet (RDP) transfusion is a rare complication of transfusion without any well-documented case reported in the English language literature. We describe 2 patients in whom TRALI occurred following RDP transfusion. Methods: Conventional clinical and laboratory methods. Results: Both patients developed acute shortness of breath 30-60 min after completion of RDP transfusion and required mechanical ventilatory support. Chest X-ray (CXR) in both cases revealed bilateral pulmonary infiltrates. Patient 1 required vasopressors for hypotension. Right heart catheterization ruled out fluid overload. Patient 2 remained hemodynamically stable. Both patients improved rapidly with continued respiratory support and were extubated within 48 h. CXR at this time showed clearing of infiltrates. In both cases a granulocyte antibody was identified in the plasma of a platelet donor supporting the diagnosis of TRALI. Conclusions: In suspected cases of TRALI. HLA and granulocyte antibody testing is indicated for the recipients and for donors of implicated components. Implicated donors need not be excluded from the donor pool, but can be used for fractionated plasma and plasma-free components.
Transfusion‐induced Platelet Antibodies and Regulatory T Cells in Multiply Transfused Patients

Tiejun Song,Ying Zhang,Jun Huang,Zhiwei Liu

DOI: https://doi.org/10.1002/jcla.23864

IF: 3.124

2021-01-01

Journal of Clinical Laboratory Analysis

Abstract:Background Platelet transfusion refractoriness (PTR) remains a difficult problem in patients requiring long-term platelet supportive care. However, there are little data on the frequency of platelet antibodies in multiply transfused Chinese patients. Moreover, the relationship between peripheral regulatory T cells (Tregs) and PTR remains unclear. Methods We retrospectively studied the frequency of alloimmunization against platelet antigens in patients receiving multiple transfusions between 2013 and 2017. Monoclonal antibody solid-phase platelet antibody test (MASPAT) kits were used to screen for platelet antibodies before each platelet transfusion. Peripheral Tregs and CD4(+)CD25(+)CD127(-) T cells were detected by flow cytometry, while transforming growth factor-beta (TGF-beta) and interleukin (IL)-17 cytokines were detected by enzyme-linked immunosorbent assay. Results A total of 399 patients who met the inclusion criteria were enrolled for the analysis of platelet antibodies and refractoriness. Among these patients, 10 (2.5%) were positive for platelet antibodies before transfusion and 47 (11.8%) became antibody-positive during the study period. The number of alloimmunized patients was significantly higher in patients with hematological disease as compared with other disease groups (p < 0.05). Refractoriness and alloimmunization occurred in 77 (19.3%) and 22 (28.6%) patients, respectively. There were no significant differences in CD4(+), CD8(+), and CD4(+)CD25(+)CD127(-) T cell numbers and plasma levels of TGF-beta 1 and IL-17 between patients with PTR and the control group. Conclusions Refractoriness was common in patients undergoing multiple platelet transfusions (19.3%), with alloimmunization observed in 28.6% of patients. However, Tregs in peripheral blood may not play a key role in PTR.
Differences in efficacy of monepantel, derquantel and abamectin against multi-resistant nematodes of sheep

R. Kaminsky,B. Bapst,P. Stein,G. Strehlau,Brooke A. Allan,B. Hosking,P. Rolfe,H. Sager

DOI: https://doi.org/10.1007/s00436-010-2216-0

2010-12-16

Parasitology Research

Abstract:
Targeting mast cell activation alleviates anti-MHC I antibody and LPS-induced TRALI in mice by pharmacologically blocking the TLR3 and MAPK pathway

Xiaobin Fang,Tianjiao Song,Ling Zheng,Yueyi Weng,Fei Gao,Chunheng Mo,Xiaochun Zheng

DOI: https://doi.org/10.1016/j.biopha.2024.117456

Abstract:Transfusion-related lung injury (TRALI) poses a significant risk following blood transfusion and remains the primary cause of transfusion-related morbidity and mortality, primarily driven by the activation of immune cells through anti-major histocompatibility complex class I (anti-MHC I) antibody. However, it remains to be defined how immune microenvironmental cue contributes to TRALI. Here, we uncover that activated mast cells within the immune microenvironment promote lung inflammation and injury in antibody-mediated TRALI, both in vitro and in vivo. This was demonstrated by co-culturing lipopolysaccharide (LPS)-pretreated mast cell line with anti-MHC I antibody and establishing a "two-hit" TRALI mouse model through intratracheal injection of LPS followed by tail-vein injection of anti-MHC I antibody. Importantly, mast cell-deficient KitW-sh/W-sh mice exhibited markedly reduced lung inflammation and injury responses in antibody-mediated TRALI compared with wild-type mice. Mechanistically, activation of toll-like receptor 3 (TLR3)/mitogen-activated protein kinase (MAPK) signaling pathway in mast cells contributes to the enhanced production of proinflammatory factors. These excessive proinflammatory factors produced by activated mast cells contribute to lung inflammation and injury in antibody-mediated TRALI. Pharmacologically targeting the TLR3/MAPK pathway to inhibit mast cell activation normalizes the proinflammatory microenvironment and alleviates lung inflammation and injury in the preclinical TRALI mouse model. Overall, we find that activation of mast cells via the TLR3/MAPK pathway contributes to lung inflammation and injury in antibody-mediated TRALI, providing novel insights into its underlying mechanisms. Furthermore, targeting activated mast cells and the associated pathway offers potential therapeutic strategies for antibody-mediated TRALI.
Transfusion‐related acute lung injury induced by human leucocyte antigen‐II antibodies: Analysis of antibody typing and source

Zou Yu,Zheng Mao,Liao Xiuyun,Jiang Tianhua

DOI: https://doi.org/10.1111/vox.13703

2024-06-27

Vox Sanguinis

Abstract:Background and Objectives To explore transfusion‐related acute lung injury (TRALI) induced by human leucocyte antigen (HLA)‐II antibodies, and to analyse antibody typing and source. Materials and Methods We retrospectively analysed the clinical symptoms and signs of two leukaemia patients with suspected TRALI from the same female donor. HLA phenotyping was performed on the two patients, the platelet donor, her husband and her two children. The HLA and human neutrophil antigen antibodies in the donor's plasma were identified. Results The clinical manifestations of two leukaemia patients were those of TRALI, and we treated them with timely ventilator support. A high titre of HLA‐II antibodies was in the plasma of the platelet donor. The antibodies were directed at HLA‐DRB3*03:01, HLA‐DRB1*09:01, HLA‐DRB1*12:02, HLA‐DRB3*01:01 and HLA‐DRB1*12:01:01G, which were specific to the HLA antigens of the two patients. High‐resolution HLA genotyping suggested that the donor's HLA‐II antibodies were derived from immune stimulation by the husband's antigens during pregnancy. Conclusions This study described two cases of TRALI caused by HLA‐II antibodies from the same female donor. Appropriate management of blood donors with a history of multiple pregnancies is crucial.

hematology
Plasma and lipids from stored platelets cause acute lung injury in an animal model

Christopher C. Silliman,A. Jason Bjornsen,Travis H. Wyman,Marguerite Kelher,Jenny Allard,Sarah Bieber,Norbert F. Voelkel

DOI: https://doi.org/10.1046/j.1537-2995.2003.00385.x

2003-04-16

Transfusion

Abstract:BACKGROUND: Transfusion of PLT concentrates may cause TRALI, a life-threatening reaction that has been linked to the infusion of anti-WBC immunoglobulins or older, stored PLTs that contain bioactive lipids. We hypothesize that lipids generated during storage of PLTs cause TRALI in a two-event animal model.STUDY DESIGN AND METHODS: Plasma from both whole-blood PLTs (WB-PLTs) and apheresis PLTs (A-PLTs) was isolated on Day 0 (D.0) and Day 5 (D.5) of storage and heat-treated before use. Rats were pretreated with saline or 2 mg per kg endotoxin (LPS), anesthetized, and the lungs were ventilated, isolated, and perfused with saline or 5-percent PLT plasma. Pulmonary artery pressure, pulmonary edema, and leukotriene B4 levels (perfusate) were measured.RESULTS: Plasma from D.5, but not D.0, of the identical WB-PLT and A-PLT units caused injury in lungs from LPS-pretreated rats (LPS/D.5) evidenced by increases in pulmonary edema and leukotriene B4 (p < 0.05). Lipid extracts and purified lipids from D.5 PLT plasma also elicited injury in lungs from LPS-pretreated rats (p < 0.05). Saline/D.5 plasma or lipids or LPS/D.0 did not cause pulmonary edema. Prestorage WBC reduction was ineffective in inhibiting TRALI.CONCLUSION: PLT-induced TRALI may be the result of two events: 1) the clinical condition of the patient and 2) the infusion of lipids in stored PLTs.

hematology
A consensus redefinition of transfusion‐related acute lung injury

Alexander P.J. Vlaar,Pearl Toy,Mark Fung,Mark R. Looney,Nicole P. Juffermans,Juergen Bux,Paula Bolton‐Maggs,Anna L. Peters,Christopher C. Silliman,Daryl J. Kor,Steve Kleinman

DOI: https://doi.org/10.1111/trf.15311

2019-04-16

Transfusion

Abstract:Transfusion‐related acute lung injury (TRALI) is a serious complication of blood transfusion and is among the leading causes of transfusion‐related morbidity and mortality in most developed countries. In the past decade, the pathophysiology of this potentially life‐threatening syndrome has been increasingly elucidated, large cohort studies have identified associated patient conditions and transfusion risk factors, and preventive strategies have been successfully implemented. These new insights provide a rationale for updating the 2004 consensus definition of TRALI.An international expert panel used the Delphi methodology to develop a redefinition of TRALI by modifying and updating the 2004 definition. Additionally, the panel reviewed issues related to TRALI nomenclature, patient conditions associated with acute respiratory distress syndrome (ARDS) and TRALI, TRALI pathophysiology, and standardization of reporting of TRALI cases.In the redefinition, the term "possible TRALI" has been dropped. The terminology of TRALI Type I (without an ARDS risk factor) and TRALI Type II (with an ARDS risk factor or with mild existing ARDS) is proposed. Cases with an ARDS risk factor that meet ARDS diagnostic criteria and where respiratory deterioration over the 12 hours before transfusion implicates the risk factor as causative should be classified as ARDS. TRALI remains a clinical diagnosis and does not require detection of cognate white blood cell antibodies.Clinicians should report all cases of posttransfusion pulmonary edema to the transfusion service so that further investigation can allow for classification of such cases as TRALI (Type I or Type II), ARDS, transfusion‐associated circulatory overload (TACO), or TRALI or TACO cannot distinguish or an alternate diagnosis.

hematology
Pulmonary coagulation and fibrinolysis abnormalities that favor fibrin deposition in the lungs of mouse antibody-mediated transfusion-related acute lung injury

Yunhong Yu,Peng Jiang,Pan Sun,Na Su,Fangzhao Lin

DOI: https://doi.org/10.3892/mmr.2021.12239

IF: 3.423

2021-06-23

Molecular Medicine Reports

Abstract:Transfusion‑related acute lung injury (TRALI) is a life‑threatening disease caused by blood transfusion. However, its pathogenesis is poorly understood and specific therapies are not available. Experimental and clinical studies have indicated that alveolar fibrin deposition serves a pathological role in acute lung injuries. The present study investigated whether pulmonary fibrin deposition occurs in a TRALI mouse model and the possible mechanisms underlying this deposition. The TRALI model was established by priming male Balb/c mice with lipopolysaccharide (LPS) 18 h prior to injection of an anti‑major histocompatibility complex class I (MHC‑I) antibody. Untreated mice and mice administered LPS plus isotype antibody served as controls. At 2 h after TRALI induction, blood and lung tissue were collected. Disease characteristics were assessed based on lung tissue histology, inflammatory responses and alterations in the alveolar‑capillary barrier. Immunofluorescence staining was used to detect pulmonary fibrin deposition, platelets and fibrin‑platelet interactions. Levels of plasminogen activator inhibitor‑1 (PAI‑1), thrombin‑antithrombin complex (TATc), tissue factor pathway inhibitor (TFPI), coagulation factor activity and fibrin degradation product (FDP) in lung tissue homogenates were measured. Severe lung injury, increased inflammatory responses and a damaged alveolar‑capillary barrier in the LPS‑primed, anti‑MHC‑I antibody‑administered mice indicated that the TRALI model was successfully established. Fibrin deposition, fibrin‑platelet interactions and platelets accumulation in the lungs of mouse models were clearly promoted. Additionally, levels of TATc, coagulation factor V (FV), TFPI and PAI‑1 were elevated, whereas FDP level was decreased in TRALI mice. In conclusion, both impaired fibrinolysis and enhanced coagulation, which might be induced by boosted FV activity, increased pulmonary platelets accumulation and enhanced fibrin‑platelet interactions and contributed to pulmonary fibrin deposition in TRALI mice. The results provided a therapeutic rationale to target abnormalities in either coagulation or fibrinolysis pathways for antibody‑mediated TRALI.

oncology,medicine, research & experimental
Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review

Jean Luc Baudel,Clara Vigneron,Veronique Pras-Landre,Jérémie Joffre,Frédéric Marjot,Hafid Ait-Oufella,Naike Bigé,Eric Maury,Bertrand Guidet,Olivier Fain,Arsène Mekinian

DOI: https://doi.org/10.1007/s10067-019-04832-7

2019-11-23

Clinical Rheumatology

Abstract:Key Points• TRALI must now be discussed in cases of respiratory distress occurring during or immediately following an infusion of intravenous immunoglobulins.

rheumatology
Extracellular vesicles in fresh frozen plasma and cryoprecipitate: Impact on in vitro endothelial cell viability

Ji Hui Hwang,John‐Paul Tung,Damien G. Harkin,Robert L. Flower,Natalie M. Pecheniuk

DOI: https://doi.org/10.1111/trf.17959

2024-07-19

Transfusion

Abstract:Background Transfusion‐related acute lung injury (TRALI) remains a major contributor to transfusion‐associated mortality. While the pathogenesis of TRALI remains unclear, there is evidence of a role for blood components. We therefore investigated the potential effects of fresh frozen plasma (FFP), cryoprecipitate, and extracellular vesicles (EVs) derived from these blood components, on the viability of human lung microvascular endothelial cells (HLMVECs) in vitro. Methods EVs were isolated from FFP and cryoprecipitate using size‐exclusion chromatography and characterized by nanoparticle tracking analysis, western blotting, and transmission electron microscopy. The potential effects of these blood components and their EVs on HLMVEC viability (determined by trypan blue exclusion) were examined in the presence and absence of neutrophils, either with or without prior treatment of HLMVECs with LPS. Results EVs isolated from FFP and cryoprecipitate displayed morphological and biochemical properties conforming to latest international criteria. While FFP, cryoprecipitate, and EVs derived from FFP, each reduced HLMVEC viability, no effect was observed for EVs derived from cryoprecipitate. Conclusion Our findings demonstrate clear differences in the effects of FFP, cryoprecipitate, and their respective EVs on HLMVEC viability in vitro. Examination of the mechanisms underlying these differences may lead to an improved understanding of the factors that promote development of TRALI.

hematology
Mechanism of TLR4 mediated immune effect in transfusion-induced acute lung injury based on Slit2/Robo4 signaling pathway

Kun Xiao,Fei Zhao,WenJie Xie,Jian Ding,XiaoAn Gong,ChenSi OuYang,Ai Ping Le

DOI: https://doi.org/10.1016/j.transci.2022.103500

Abstract:Background: Transfusion-related acute lung injury (TRALI) is the infusion of blood or blood system. Objective: To explore the mechanism of TLR4-mediated T cell immune effect in TRALI. Methods: In this animal study, a mouse model of LPS-induced TRALI was established. Sixty adult C57/BL6 mice (wild-type, WT) were randomly divided into 5 groups: 1) normal WT type, 2) LPS control group of WT type lipopolysaccharide, 3) WT type TRALI group (LPS + MHC-I mAb), 4) (TLR4 antibody) lipopolysaccharide LPS control group, 5) (TLR4 antibody) TRALI group (LPS + MHC-I mAb). Mice were injected with LPS (0.1 mg/kg) and MHC-I mAb (2 mg/kg) into the tail vein. H&E staining was performed to detect pathological features. The myeloperoxidase (MPO) activity and the level of inflammatory cytokines in lung tissue homogenate supernatant were measured. Blood, spleen single-cell suspension, and bronchoalveolar lavage fluid were collected to detect the ratio of Treg and Th17 cells by flow cytometry. RT-PCR and WB were used to detect mRNA or protein expression. Results: TLR4 mAb treatment alleviated the pathogenesis of LPS-induced TRALI in vivo, the MPO activity, and the level of proinflammatory factors in lung tissues. TLR4 exerted its function by changing of Treg/Th17 ratio via the SLIT2/ROBO4 signaling pathway and downregulating CDH5 and SETSIP. Conclusion: TLR4 mediates immune response in the LPS-induced TRALI model through the SLIT2/ROBO4 signaling pathway.
Fine needle aspiration of an unusual malignant mixed tumor in the parotid gland.

Xiu Yang,A. Cole,M. Oktay,Richard V. Smith,A. Cajigas,S. Khader

DOI: https://doi.org/10.1309/LMEKYOLQ2J5ZOO7O

2014-05-01

LaboratoriumsMedizin

Abstract:OBJECTIVE The use of fine needle aspiration (FNA) biopsy in the triage of salivary gland tumors has been well established. The sensitivity and specificity of FNA biopsy for tumor diagnosis is generally very good. However, the diagnosis can be challenging due to the limited amount of tissue sampled, the occasional overlapping tumor morphology, and the presence of a malignant counterpart of a benign tumor. METHODS FNA biopsy was performed with ultrasound guidance. Air-dried slides and alcohol-fixed slides were made for Diff-Quik staining and Papanicolaou staining, respectively. The syringes were rinsed and a cell block was prepared. The resected specimen was fixed in 10% formalin and processed by routine histology techniques. RESULTS We report a rare case of a salivary gland neoplasm with 2 distinct components: adenoid cystic carcinoma and pleomorphic adenoma. These 2 components are clearly identifiable in both cytological materials from fine needle aspiration and histological analysis of surgical resection. CONCLUSION Pleomorphic adenoma is the most common salivary gland tumor for patients in all age groups. The characteristic cytological feature is fibrillary extracellular matrix intermixed with epithelial cells. Malignant transformation occurs in 5% to 10% of cases. Rarely, pleomorphic adenoma exists as one component of a hybrid tumor. The surgical resection will be needed in those cases. The final diagnosis relies on the combination of the clinical information, histological findings and molecular study.
Developments in Transfusion Medicine: Pulmonary Transfusion Reactions and Novel Blood Cell Labeling Techniques

Philippa G Phelp,Stefan F van Wonderen,Alexander P J Vlaar,Rick Kapur,Robert B Klanderman

DOI: https://doi.org/10.1213/ANE.0000000000007136

2024-09-13

Abstract:Staying updated on advancements in transfusion medicine is crucial, especially in critical care and perioperative setting, where timely and accurate transfusions can be lifesaving therapeutic interventions. This narrative review explores the landscape of transfusion-related adverse events, focusing on pulmonary transfusion reactions such as transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI). TACO and TRALI are the leading causes of transfusion-related morbidity and mortality; however, specific treatments are lacking. Understanding the current incidence, diagnostic criteria, pathogenesis, treatment, and prevention strategies can equip clinicians to help reduce the incidence of these life-threatening complications. The review discusses emerging pathogenic mechanisms, including the possible role of inflammation in TACO and the mechanisms of reverse TRALI and therapeutic targets for TACO and TRALI, emphasizing the need for further research to uncover preventive and treatment modalities. Despite advancements, significant gaps remain in our understanding of what occurs during transfusions, highlighting the necessity for improved monitoring methods. To address this, the review also presents novel blood cell labeling techniques in transfusion medicine used for improving monitoring, quality assessment, and as a consequence, potentially reducing transfusion-related complications. This article aims to provide an update for anesthesiologists, critical care specialists, and transfusion medicine professionals regarding recent advancements and developments in the field of transfusion medicine.
Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions

Hayley R Waterman,Linda M Kapp,Adam Munday,Katherine Odem-Davis,James C Zimring

DOI: https://doi.org/10.1111/trf.13270

Transfusion

Abstract:Background: Platelet (PLT) transfusions can be an essential therapy for patients with thrombocytopenia to maintain hemostasis. However, some patients become alloimmunized to antigens on PLTs (typically HLA), which can prevent efficacy of PLT transfusion due to antibody-mediated clearance. In extreme cases, patients with alloimmunization to multiple HLAs can become "refractory" to PLT transfusion, such that insufficient compatible PLT units can be found to meet transfusion needs. Materials and methods: An in vivo murine model of PLT-induced alloimmunization was refined so as to include both transfusion with allogeneic leukoreduced PLTs and studies of posttransfusion PLT recoveries, allowing assessment of alloimmunization and refractoriness. Basic mechanisms of antibody-mediated PLT clearance were investigated using recipients missing either the C3 complement gene or the common gamma chain for Fc receptors. In addition, the efficacy of using costimulatory blockade as a therapeutic intervention was assessed by testing CTLA4-Ig administration before PLT transfusion. Results: Fcγ receptors (but not complement C3) are required for alloantibody-mediated PLT refractoriness. In addition, levels of anti-MHC predict the extent of refractoriness in a given animal. Finally, costimulatory blockade as a therapeutic modality prevents transfusion-induced PLT refractoriness. Conclusions: Together these findings introduce new experimental methods, basic mechanistic understanding, and a potential therapeutic intervention for alloimmunization to MHC-based antigens on transfused PLTs.
Individual differences in the relationship transition context: links to physiological outcomes.

Elizabeth Keneski,E. Schoenfeld,T. Loving

DOI: https://doi.org/10.1111/jopy.12057

IF: 5.429

2014-12-01

Journal of Personality

Abstract:The identification of relationship-relevant individual differences is central to elucidating how relationship experiences differentially impact individuals' health. To this end, we highlight the utility of studying the influence of individual differences on physiological outcomes (e.g., cortisol reactivity and recovery) in the context of normative relationship transitions. We argue that relationship transitions, such as falling in love and the process of committing to marry one's partner, amplify the influence of individual differences on relationship processes and, by extension, on physiological outcomes. Two such individual differences are highlighted-namely, relationship-focused processing and dependence-and suggestions for future work are provided.

Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.

Plasma From Stored Packed Red Blood Cells And Mhc Class I Antibodies Causes Acute Lung Injury In A 2-Event In Vivo Rat Model

A pulmonary endothelial amplification loop aggravates ex‐vivo transfusion‐related acute lung injury via increased toll‐like receptor 4 and intra‐cellular adhesion molecule‐1 expression

Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies

Sheet resistance measurement for process monitoring of 400 °C PureB deposition on Si

MEASUREMENT OF THE LONGITUDINAL POLARIZATION OF THE HERA ELECTRON BEAM USING CRYSTALS AND THE ZEUS LUMINOSITY MONITOR

Transfusion-related acute lung injury following random donor platelet transfusion: a report of two cases

Transfusion‐induced Platelet Antibodies and Regulatory T Cells in Multiply Transfused Patients

Differences in efficacy of monepantel, derquantel and abamectin against multi-resistant nematodes of sheep

Targeting mast cell activation alleviates anti-MHC I antibody and LPS-induced TRALI in mice by pharmacologically blocking the TLR3 and MAPK pathway

Transfusion‐related acute lung injury induced by human leucocyte antigen‐II antibodies: Analysis of antibody typing and source

Plasma and lipids from stored platelets cause acute lung injury in an animal model

A consensus redefinition of transfusion‐related acute lung injury

Pulmonary coagulation and fibrinolysis abnormalities that favor fibrin deposition in the lungs of mouse antibody-mediated transfusion-related acute lung injury

Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review

Extracellular vesicles in fresh frozen plasma and cryoprecipitate: Impact on in vitro endothelial cell viability

Mechanism of TLR4 mediated immune effect in transfusion-induced acute lung injury based on Slit2/Robo4 signaling pathway

Fine needle aspiration of an unusual malignant mixed tumor in the parotid gland.

Developments in Transfusion Medicine: Pulmonary Transfusion Reactions and Novel Blood Cell Labeling Techniques

Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions

Individual differences in the relationship transition context: links to physiological outcomes.